Can a denser dose of rituximab stop ITP relapses in kids?

NCT ID NCT04323748

Recruiting now Disease control Sponsor: New York Medical College Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated May 22, 2026 · Updated 7 times

Summary

This study tests whether giving rituximab more frequently (dose dense) can improve remission and reduce relapse in children and teens aged 1 to 21 with newly diagnosed, high-risk immune thrombocytopenic purpura (ITP). Participants must have a very low platelet count and at least one high-risk feature like age 10 or older, significant bleeding, or a positive ANA test. The study will monitor safety and how many patients achieve a stable platelet count without needing long-term medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIC PURPURA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

New York Medical College
RECRUITING

Vahalla, New York, 10595, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

IMMUNE THROMBOCYTOPENIC PURPURA